We are pleased to announce the publication of our studies in Nature Nanotechnology showcasing the capabilities of our bottlebrush analogue macromolecule (BAM) technology. In the context of multiple myeloma, we (1) introduce a next-generation proteasome inhibitor with improved potency and safety, (2) demonstrate that multi-drug synergy can be translated in a streamlined manner based on the established regimen of bortezomib, pomalidomide, and dexamethasone. (https://www.nature.com/articles/s41565-022-01310-1)
Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma
